RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/fGaTc7M0LJ https://t.co/…
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleague…
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice | SpringerLink https://t.co/sYGiBvhUBH
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleague…
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleague…
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleague…
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleague…
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleague…
RT @DrRaniKhatib: Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/fGaTc7M0LJ https://t.co/…
Very useful Benefit/risk tool for initiation of SGLT2i. Thank you @drkevinfernando: https://t.co/QnmGxshLz6
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleague…
@DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf Have a look at this article that several colleagues and I wrote with a SGLT m2 risk benefit tool included - it’s an open access article https://t.co/us4v2YO0u2
@kevbizarre @mark_borthwick @CardioPharmUK Unfortunately depending on your criteria these two articles are industry funded (to get us in the room together) but had no input into output /content of these two articles - I wouldnt be involved otherwise http
@alicia_bentham I found this article from the same authors very useful as well, in particular Figure 3 which considers the risks and benefits of SGLT-2 inhibitors in different situations: https://t.co/DmhHzaii1X
@a_walsingham This is a really useful article summarising the key evidence for SGLT-2 inhibitors. Also covers some of the practical issues to consider when prescribing them. https://t.co/DmhHzaii1X
@drpatrickholmes @AbdTahrani @bananabeba @lauraloughran88 @kamleshkhunti @PokrajacAna @drkevinfernando https://t.co/7gcuwNLzIw fairly comprehensive and holds up
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
1/ Napp Pharmaceuticals has exclusive rights to distribute SGLT" in the UK https://t.co/KTB8YTMRqz Napp Pharmacueticals funds research into clinical benefits of SGLT2 for T2 diabetes https://t.co/jFW5lrmZuP by crating a tool to show who will benefit for
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice #diabetes https://t.co/VEmRhoHt7d
Uitstekend artikel waarin de indicaties en contra-indicaties van het gebruik van SGLT2-remmers helder worden beschreven. #diabetes #SGLT2 https://t.co/UFUnial5L8
RT @drnkan: About time. Make it more accessible for use in primary care #diabetes https://t.co/BHIwyizaZn
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @neuropadtest: As good a reason as any for the option of widespread .@neuropadtest screening: 'Ongoing monitoring and preventative footc…
As good a reason as any for the option of widespread .@neuropadtest screening: 'Ongoing monitoring and preventative footcare advice should be provided for those receiving SGLT2i medicines.' https://t.co/ZTdFvzv3x2 https://t.co/9XKVXjCLWb
RT @neuropadtest: In patients at low or moderate risk wouldn't it be sensible to screen for early signs of dibetic peripheral neuropathy us…
In patients at low or moderate risk wouldn't it be sensible to screen for early signs of dibetic peripheral neuropathy using a #tenminutetest perhaps? https://t.co/ZTdFvzv3x2 https://t.co/i5ReUga4tv
RT @SoarBeyondLtd: Useful paper by @PNewlandJones et al on this class of drugs- covered amongst the rest @i2iPharmacist diabetes workshops…
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @SolentDSNs: Fab new paper from one of our fab colleagues on SGLT2 prescribing.. it includes a great quick and easy tool to use when loo…
RT @pharman: Practical points here which enhance need and role of pharmacy... https://t.co/72BT029JuF
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
Fab new paper from one of our fab colleagues on SGLT2 prescribing.. it includes a great quick and easy tool to use when looking at risks with these meds.. https://t.co/pdqcmygfW4
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
Practical points here which enhance need and role of pharmacy... https://t.co/72BT029JuF
Very useful summary https://t.co/vA9GWtTm7y
RT @drnkan: About time. Make it more accessible for use in primary care #diabetes https://t.co/BHIwyizaZn
RT @drnkan: About time. Make it more accessible for use in primary care #diabetes https://t.co/BHIwyizaZn
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @drnkan: About time. Make it more accessible for use in primary care #diabetes https://t.co/BHIwyizaZn
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @drjamesboyle: Really practical paper (see images!) from John Wilding, Steve Bain, @PNewlandJones @nicmiln @drkevinfernando et al. in @D…
RT @drnkan: About time. Make it more accessible for use in primary care #diabetes https://t.co/BHIwyizaZn
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @drnkan: About time. Make it more accessible for use in primary care #diabetes https://t.co/BHIwyizaZn
RT @drnkan: About time. Make it more accessible for use in primary care #diabetes https://t.co/BHIwyizaZn
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
Useful paper by @PNewlandJones et al on this class of drugs- covered amongst the rest @i2iPharmacist diabetes workshops https://t.co/SK5bHB0XeW
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @nicmiln: Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @drkevinfernando: Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Ther…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
Really useful risk/benefit tool for use of SGLT2-is. https://t.co/dXySvO0MaR @WeGPNs @DSNforumUK https://t.co/tC57C0l3VD
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
Delighted to have been one of the authors on this open access SGLT2i review paper published yesterday in Diabetes Therapy It explores safe & appropriate use of SGLT2i’s & includes pragmatic tips such as sick day rules & a risk:benefit traffic l
RT @drjamesboyle: Really practical paper (see images!) from John Wilding, Steve Bain, @PNewlandJones @nicmiln @drkevinfernando et al. in @D…
RT @drjamesboyle: Really practical paper (see images!) from John Wilding, Steve Bain, @PNewlandJones @nicmiln @drkevinfernando et al. in @D…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @drjamesboyle: Really practical paper (see images!) from John Wilding, Steve Bain, @PNewlandJones @nicmiln @drkevinfernando et al. in @D…
Really practical paper (see images!) from John Wilding, Steve Bain, @PNewlandJones @nicmiln @drkevinfernando et al. in @Diabetes_Ther. SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice https://t.co/I1IhHVpj
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…
RT @PNewlandJones: Confused about SGLT2i? Very pleased to share our collaborative paper on: “SGLT2 Inhibitors in Type 2 Diabetes Managemen…